IRCT20180620040164N88 IRCT 2025-05-14 Gol Darou Pharmaceutical Co. Comparative in vivo evaluation of 2 formulations of Silymarin 210 mg Comparative bioequivalence study of Silymarin 210 mg Softgel of Gol Darou Pharmaceutical Co. and Silymarin 210 Hard Capsule of Gol Darou Pharmaceutical Co. in 24 healthy male under fasting 2025-06-09 anticipated 24 Complete https://irct.ir/trial/83438 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Crossover, Purpose: Treatment, Randomization description: The randomization schedule will be generated with https://www.sealedenvelope.com/simple-randomiser/v1/lists. A 2*2 block randomization list is created. We have 12 blocks and within each two volunteer numbers (allocated after screening) for all 24 volunteers. According to this list, a treatment sequence of Test/Reference or Reference/Test will be given to each volunteer. Bioequivalence Poisoning by other drugs, medicaments and biological substances, accidental (unintentional). Intervention 1: Intervention group: Silymarin 210 mg softgel , produced by Gol Darou Pharmaceutical Co. In each period, 12 of 24 subjects will be given single oral dose of this product. After 14-day wash-out period the intervention 2 will be given to these subjects. Intervention 2: Intervention group: Silymarin 210 mg hard capsule , produced by Gol Darou Pharmaceutical Co. In each period, 12 of 24 subjects will be given single oral dose of this product. After 14-day wash-out period the intervention 2 will be given to these subjec. No - There is not a plan to make this available Justification or reason for not sharing IPD is It's undetermind yet.